肝细胞癌合并微血管侵犯术后辅助治疗现状

摘要/Abstract

摘要：

肝细胞癌是一种具有强侵袭性的恶性肿瘤，尽管外科技术的进步使得单纯手术治疗取得了一定的成效，但仍无法显著改善患者的长期生存状况。研究表明，肝细胞癌术后复发率极高，而微血管侵犯则是导致早期复发和预后不佳的一个重要原因。因此，针对合并微血管侵犯的肝细胞癌患者，术后采取适当的辅助治疗措施对改善其生存预后至关重要。

关键词:癌，肝细胞,肿瘤辅助疗法,微血管侵犯

Abstract:

Hepatocellular carcinoma is a highly aggressive malignant tumor. Although the progress of surgical technology has made some achievements in surgical treatment alone， it still fails to significantly improve the long-term survival of patients. Studies have shown that the recurrence rate of hepatocellular carcinoma is extremely high， while microvascular invasion is an important reason for early recurrence and poor prognosis. Therefore， appropriate postoperative adjuvant therapy measures are crucial to improve the survival prognosis of hepatocellular carcinoma patients with microvascular invasion.

Key words:Carcinoma， hepatocellular,Neoadjuvant therapy,Microvascular invasion

徐放, 朱文钿. 肝细胞癌合并微血管侵犯术后辅助治疗现状[J]. 国际肿瘤学杂志, 2023, 50(5): 304-309.

Xu Fang, Zhu Wentian. Progress in adjuvant therapy of hepatocellular carcinoma complicated with microvascular invasion[J]. Journal of International Oncology, 2023, 50(5): 304-309.

参考文献42

[1]	中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗指南(2022年版)[J]. 中国实用外科杂志, 2022, 42(3): 241-273. DOI: 10.19538/j.cjps.issn1005-2208.2022.03.01. doi:10.19538/j.cjps.issn1005-2208.2022.03.01
[2]	夏永祥, 张峰, 李相成, 等. 原发性肝癌10966例外科治疗分析[J]. 中华外科杂志, 2021, 59(1): 6-17. DOI: 10.3760/cma.j.cn112139-20201110-00791. doi:10.3760/cma.j.cn112139-20201110-00791
[3]	Wei T, Zhang XF, Bagante F, et al. Early versus late recurrence of hepatocellular carcinoma after surgical resection based on post-recurrence survival: an international multi-institutional analysis[J]. J Gastrointest Surg, 2021, 25(1): 125-133. DOI: 10.1007/s11605-020-04553-2. doi:10.1007/s11605-020-04553-2
[4]	Kudo M, Kawamura Y, Hasegawa K, et al. Management of HepatoCellular Carcinoma in Japan: JSH Consensus Statements and Re-commendations 2021 Update[J]. Liver Cancer, 2021, 10(3): 181-223. DOI: 10.1159/000514174. doi:10.1159/000514174
[5]	丛文铭, 吴孟超. 努力提高我国肝癌微血管侵犯的精细化诊断和个体化治疗水平[J]. 中华肝胆外科杂志, 2019, 25(10): 721-724. DOI: 10.3760/cma.j.issn.1007-8118.2019.10.001. doi:10.3760/cma.j.issn.1007-8118.2019.10.001
[6]	Yamashita YI, Imai K, Yusa T, et al. Microvascular invasion of single small hepatocellular carcinoma ≤3 cm: predictors and optimal treatments[J]. Ann Gastroenterol Surg, 2018, 2(3): 197-203. DOI: 10.1002/ags3.12057. doi:10.1002/ags3.12057pmid:29863190
[7]	Yang J, Liang H, Hu K, et al. The effects of several postoperative adjuvant therapies for hepatocellular carcinoma patients with microvascular invasion after curative resection: a systematic review and meta-analysis[J]. Cancer Cell Int, 2021, 21(1): 92. DOI: 10.1186/s12935-021-01790-6. doi:10.1186/s12935-021-01790-6pmid:33549093
[8]	Chen ZH, Zhang XP, Zhou TF, et al. Adjuvant transarterial chemoembolization improves survival outcomes in hepatocellular carcinoma with microvascular invasion: a systematic review and meta-analysis[J]. Eur J Surg Oncol, 2019, 45(11): 2188-2196. DOI: 10.1016/j.ejso.2019.06.031. doi:10.1016/j.ejso.2019.06.031
[9]	Zhong JH, Li LQ. Postoperative adjuvant transarterial chemoembolization for participants with hepatocellular carcinoma: a meta-analysis[J]. Hepatol Res, 2010, 40(10): 943-953. DOI: 10.1111/j.1872-034X.2010.00710.x. doi:10.1111/j.1872-034X.2010.00710.x
[10]	Sun JJ, Wang K, Zhang CZ, et al. Postoperative adjuvant transcatheter arterial chemoembolization after R0 hepatectomy improves outcomes of patients who have hepatocellular carcinoma with microvascular invasion[J]. Ann Surg Oncol, 2016, 23(4): 1344-1351. DOI: 10.1245/s10434-015-5008-z. doi:10.1245/s10434-015-5008-z
[11]	Wang Z, Ren Z, Chen Y, et al. Adjuvant transarterial chemoembolization for HBV-related hepatocellular carcinoma after resection: a randomized controlled study[J]. Clin Cancer Res, 2018, 24(9): 2074-2081. DOI: 10.1158/1078-0432.CCR-17-2899. doi:10.1158/1078-0432.CCR-17-2899pmid:29420221
[12]	Ye JZ, Chen JZ, Li ZH, et al. Efficacy of postoperative adjuvant transcatheter arterial chemoembolization in hepatocellular carcinoma patients with microvascular invasion[J]. World J Gastroenterol, 2017, 23(41): 7415-7424. DOI: 10.3748/wjg.v23.i41.7415. doi:10.3748/wjg.v23.i41.7415
[13]	Qi YP, Zhong JH, Liang ZY, et al. Adjuvant transarterial chemoembolization for patients with hepatocellular carcinoma involving microvascular invasion[J]. Am J Surg, 2019, 217(4): 739-744. DOI: 10.1016/j.amjsurg.2018.07.054. doi:10.1016/j.amjsurg.2018.07.054
[14]	Ke-Wei L, Tian-Fu W, Xi L, et al. The effect of postoperative TACE on prognosis of HCC with microscopic venous invasion[J]. Hepatogastroenterology, 2012, 59(118): 1944-1946. DOI: 10.5754/hge11845. doi:10.5754/hge11845
[15]	Shen A, Liu M, Zheng D, et al. Adjuvant transarterial chemo-embolization after curative hepatectomy for hepatocellular carcinoma with microvascular invasion: a systematic review and meta-analysis[J]. Clin Res Hepatol Gastroenterol, 2020, 44(2): 142-154. DOI: 10.1016/j.clinre.2019.06.012. doi:10.1016/j.clinre.2019.06.012
[16]	Jiang JH, Guo Z, Lu HF, et al. Adjuvant transarterial chemoembolization after curative resection of hepatocellular carcinoma: propensity score analysis[J]. World J Gastroenterol, 2015, 21(15): 4627-4634. DOI: 10.3748/wjg.v21.i15.4627. doi:10.3748/wjg.v21.i15.4627
[17]	Wang YY, Wang LJ, Xu D, et al. Postoperative adjuvant transcatheter arterial chemoembolization should be considered selectively in patients who have hepatocellular carcinoma with microvascular invasion[J]. HPB (Oxford), 2019, 21(4): 425-433. DOI: 10.1016/j.hpb.2018.08.001. doi:10.1016/j.hpb.2018.08.001
[18]	Irie T, Kuramochi M, Kamoshida T, et al. Selective balloon-occluded transarterial chemoembolization for patients with one or two hepatocellular carcinoma nodules: retrospective comparison with conventional super-selective TACE[J]. Hepatol Res, 2016, 46(2): 209-214. DOI: 10.1111/hepr.12564. doi:10.1111/hepr.12564pmid:26224032
[19]	Ogawa M, Takayasu K, Hirayama M, et al. Efficacy of a microballoon catheter in transarterial chemoembolization of hepatocellular carcinoma using miriplatin, a lipophilic anticancer drug: short-term results[J]. Hepatol Res, 2016, 46(3): E60-E69. DOI: 10.1111/hepr.12527. doi:10.1111/hepr.12527
[20]	Lewandowski RJ, Geschwind JF, Liapi E, et al. Transcatheter intraarterial therapies: rationale and overview[J]. Radiology, 2011, 259(3): 641-657. DOI: 10.1148/radiol.11081489. doi:10.1148/radiol.11081489pmid:21602502
[21]	Li S, Mei J, Wang Q, et al. Correction to: postoperative adjuvant transarterial infusion chemotherapy with FOLFOX could improve outcomes of hepatocellular carcinoma patients with microvascular invasion: a preliminary report of a phase Ⅲ, randomized controlled clinical trial[J]. Ann Surg Oncol, 2021, 28(Suppl 3): 874. DOI: 10.1245/s10434-021-09813-2. doi:10.1245/s10434-021-09813-2
[22]	Wang L, Wang W, Rong W, et al. Postoperative adjuvant treatment strategy for hepatocellular carcinoma with microvascular invasion: a non-randomized interventional clinical study[J]. BMC Cancer, 2020, 20(1): 614. DOI: 10.1186/s12885-020-07087-7. doi:10.1186/s12885-020-07087-7pmid:32611327
[23]	Chen B, Wu JX, Cheng SH, et al. Phase 2 study of adjuvant radiotherapy following narrow-margin hepatectomy in patients with HCC[J]. Hepatology, 2021, 74(5): 2595-2604. DOI: 10.1002/hep.31993. doi:10.1002/hep.31993pmid:34097307
[24]	Wahl DR, Stenmark MH, Tao Y, et al. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma[J]. J Clin Oncol, 2016, 34(5): 452-459. DOI: 10. 1200/JCO.2015.61.4925. doi:10.1200/JCO.2015.61.4925pmid:26628466
[25]	Ohri N, Dawson LA, Krishnan S, et al. Radiotherapy for hepatocellular carcinoma: new indications and directions for future study[J]. J Natl Cancer Inst, 2016, 108(9): djw133. DOI: 10.1093/jnci/djw133. doi:10.1093/jnci/djw133
[26]	Shi C, Li Y, Geng L, et al. Adjuvant stereotactic body radiotherapy after marginal resection for hepatocellular carcinoma with microvascular invasion: a randomised controlled trial[J]. Eur J Cancer, 2022, 166: 176-184. DOI: 10.1016/j.ejca.2022.02.012. doi:10.1016/j.ejca.2022.02.012pmid:35303509
[27]	Zhang XP, Chai ZT, Gao YZ, et al. Postoperative adjuvant sorafenib improves survival outcomes in hepatocellular carcinoma patients with microvascular invasion after R0 liver resection: a propensity score matching analysis[J]. HPB (Oxford), 2019, 21(12): 1687-1696. DOI: 10.1016/j.hpb.2019.04.014. doi:10.1016/j.hpb.2019.04.014
[28]	Huang S, Li D, Zhuang L, et al. A meta-analysis of the efficacy and safety of adjuvant sorafenib for hepatocellular carcinoma after resection[J]. World J Surg Oncol, 2021, 19(1): 168. DOI: 10.1186/s12957-021-02280-9. doi:10.1186/s12957-021-02280-9pmid:34112190
[29]	Bi X, Gao J, Cai J, et al. Sorafenib versus transarterial chemo-embolization as adjuvant therapies for patients with hepatocellular carcinoma and microvascular invasion[J]. J Clin Oncol, 2019, 37(4_suppl): 244. DOI: 10.1200/JCO.2019.37.4_suppl.244. doi:10.1200/JCO.2019.37.4_suppl.244
[30]	Qin S, Bi F, Gu S, et al. Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma: a randomized, open-label, parallel-controlled phase Ⅱ-Ⅲ trial[J]. J Clin Oncol, 2021, 39(27): 3002-3011. DOI: 10.1200/JCO.21.00163. doi:10.1200/JCO.21.00163
[31]	Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382(20): 1894-1905. DOI: 10.1056/NEJMoa1915745. doi:10.1056/NEJMoa1915745
[32]	Finn RS, Qin S, Ikeda M, et al. iMbrave150: updated overall survival (OS) data from a global, randomized, open-label phase Ⅲ study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC)[J]. J Clin Oncol, 2021, 39(3_suppl): 267. DOI: 10.1200/JCO.2021.39.3_suppl.267. doi:10.1200/JCO.2021.39.3_suppl.267
[33]	Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study[J]. Lancet Oncol, 2021, 22(7): 977-990. DOI: 10.1016/S1470-2045(21)00252-7. doi:10.1016/S1470-2045(21)00252-7
[34]	Qin S, Ren Z, Meng Z, et al. Camrelizumab in patients with pre-viously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial[J]. Lancet Oncol, 2020, 21(4): 571-580. DOI: 10.1016/S1470-2045(20)30011-5. doi:10.1016/S1470-2045(20)30011-5
[35]	Wang J, Sanmamed MF, Datar I, et al. Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3[J]. Cell, 2019, 176(1/2): 334-347.e12. DOI: 10.1016/j.cell.2018.11.010. doi:10.1016/j.cell.2018.11.010
[36]	Wang J, Sun J, Liu LN, et al. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy[J]. Nat Med, 2019, 25(4): 656-666. DOI: 10.1038/s41591-019-0374-x. doi:10.1038/s41591-019-0374-xpmid:30833750
[37]	Peng Z, Chen S, Xiao H, et al. Microvascular invasion as a predictor of response to treatment with sorafenib and transarterial chemo-embolization for recurrent intermediate-stage hepatocellular carcinoma[J]. Radiology, 2019, 292(1): 237-247. DOI: 10.1148/radiol.2019181818. doi:10.1148/radiol.2019181818
[38]	Wang B, Xu H, Gao ZQ, et al. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization[J]. Acta radiol, 2008, 49(5): 523-529. DOI: 10.1080/02841850801958890. doi:10.1080/02841850801958890pmid:18568538
[39]	Wang C, Liao Y, Qiu J, et al. Transcatheter arterial chemoembolization alone or combined with ablation for recurrent intermediate-stage hepatocellular carcinoma: a propensity score matching study[J]. J Cancer Res Clin Oncol, 2020, 146(10): 2669-2680. DOI: 10.1007/s00432-020-03254-2. doi:10.1007/s00432-020-03254-2pmid:32449005
[40]	Lin CW, Chen YS, Lo GH, et al. Comparison of overall survival on surgical resection versus transarterial chemoembolization with or without radiofrequency ablation in intermediate stage hepatocellular carcinoma: a propensity score matching analysis[J]. BMC Gastroenterol, 2020, 20(1): 99. DOI: 10.1186/s12876-020-01235-w. doi:10.1186/s12876-020-01235-w
[41]	Roger A, Finet A, Boru B, et al. Efficacy of combined hypo-fractionated radiotherapy and anti-PD-1 monotherapy in difficult-to-treat advanced melanoma patients[J]. Oncoimmunology, 2018, 7(7): e1442166. DOI: 10.1080/2162402X.2018.1442166. doi:10.1080/2162402X.2018.1442166
[42]	Chen L, Douglass J, Walker AJ, et al. Concurrent immunotherapy and stereotactic radiosurgery for brain metastases is associated with a decreased incidence of new intracranial metastases[J]. Int J Radiat Oncol Biol Phys, 2015, 93(3 SUPPL): E102. DOI: 10.1016/j.ijrobp.2015.07.807. doi:10.1016/j.ijrobp.2015.07.807